Nymox Pharma Wins Lawsuit Dismissal
Ticker: NYMXF · Form: 6-K · Filed: Nov 7, 2025 · CIK: 1018735
| Field | Detail |
|---|---|
| Company | Nymox Pharmaceutical CORP (NYMXF) |
| Form Type | 6-K |
| Filed Date | Nov 7, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: legal-win, litigation, dismissal
TL;DR
Nymox wins lawsuit dismissal, case closed with prejudice.
AI Summary
Nymox Pharmaceutical Corporation announced on November 7, 2025, that the U.S. District Court for the Central District of California granted its motion and that of Computershare Investor Services Inc. to dismiss Christopher Riley's complaint. The case was dismissed with prejudice.
Why It Matters
This dismissal resolves a legal challenge against Nymox, potentially removing a source of uncertainty and litigation risk for the company.
Risk Assessment
Risk Level: low — The filing reports a positive legal outcome, which typically reduces risk.
Key Players & Entities
- Nymox Pharmaceutical Corporation (company) — Filer of the report and party in the lawsuit
- Computershare Investor Services Inc. (company) — Co-defendant in the lawsuit
- Christopher Riley (person) — Plaintiff in the lawsuit
- U.S. District Court for the Central District of California (company) — Court that granted the dismissal
FAQ
What was the nature of Christopher Riley's complaint against Nymox Pharmaceutical Corporation?
The filing does not specify the nature of Christopher Riley's complaint, only that it was dismissed.
What does 'dismissed with prejudice' mean in this context?
Dismissed with prejudice means the case is permanently closed and cannot be refiled by the plaintiff.
What is Nymox Pharmaceutical Corporation's principal executive office address?
Nymox Pharmaceutical Corporation's principal executive office is located at Bay & Deveaux Streets, Nassau, The Bahamas.
What is Nymox Pharmaceutical Corporation's SIC code and industry?
Nymox Pharmaceutical Corporation's SIC code is 2835, and its industry is IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.
When was this Form 6-K filed?
This Form 6-K was filed on November 7, 2025.
Filing Stats: 175 words · 1 min read · ~1 pages · Grade level 12.5 · Accepted 2025-11-07 12:29:27
Filing Documents
- nymox_6k.htm (6-K) — 9KB
- 0001640334-25-001988.txt ( ) — 10KB
From the Filing
nymox_6k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November, 2025 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant's name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Nymox Pharmaceutical Corporation (the "Company") reports that the U.S. District for the Central District of California granted the Company's and Computershare Investor Services Inc.'s motion to dismiss Christopher Riley's complaint, and dismissed the case, with prejudice. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 7, 2025 NYMOX PHARMACEUTICAL CORPORATION By: /s/ Paul Averback Name: Paul Averback Title: President and Chief Executive Officer 3